JP2007513079A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513079A5
JP2007513079A5 JP2006539072A JP2006539072A JP2007513079A5 JP 2007513079 A5 JP2007513079 A5 JP 2007513079A5 JP 2006539072 A JP2006539072 A JP 2006539072A JP 2006539072 A JP2006539072 A JP 2006539072A JP 2007513079 A5 JP2007513079 A5 JP 2007513079A5
Authority
JP
Japan
Prior art keywords
disease
copolymer
iii
pharmaceutical composition
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006539072A
Other languages
English (en)
Japanese (ja)
Other versions
JP5456235B2 (ja
JP2007513079A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2004/001037 external-priority patent/WO2005046719A1/en
Publication of JP2007513079A publication Critical patent/JP2007513079A/ja
Publication of JP2007513079A5 publication Critical patent/JP2007513079A5/ja
Application granted granted Critical
Publication of JP5456235B2 publication Critical patent/JP5456235B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006539072A 2003-11-12 2004-11-11 神経変性疾患を治療するためのワクチン及び方法 Expired - Fee Related JP5456235B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51862703P 2003-11-12 2003-11-12
US60/518,627 2003-11-12
US61096604P 2004-09-20 2004-09-20
US60/610,966 2004-09-20
PCT/IL2004/001037 WO2005046719A1 (en) 2003-11-12 2004-11-11 Vaccine and method for treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2007513079A JP2007513079A (ja) 2007-05-24
JP2007513079A5 true JP2007513079A5 (https=) 2008-01-10
JP5456235B2 JP5456235B2 (ja) 2014-03-26

Family

ID=34594916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539072A Expired - Fee Related JP5456235B2 (ja) 2003-11-12 2004-11-11 神経変性疾患を治療するためのワクチン及び方法

Country Status (7)

Country Link
US (3) US20080085269A1 (https=)
EP (2) EP1684797A1 (https=)
JP (1) JP5456235B2 (https=)
AU (1) AU2004288654B2 (https=)
CA (1) CA2546077C (https=)
IL (2) IL175535A (https=)
WO (1) WO2005046719A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2005056574A2 (en) 2003-12-09 2005-06-23 Yeda Research And Development Co. Ltd. Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
US8193147B2 (en) 2007-09-24 2012-06-05 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
WO2010019270A1 (en) * 2008-08-14 2010-02-18 Isis Pharmaceuticals, Inc. Modulation of prion expression
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
WO2013059322A2 (en) * 2011-10-17 2013-04-25 Lawrence Steinman Amyloid beta peptide as a therapy for inflammation
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
AU2015228372B2 (en) 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN109600992A (zh) * 2016-05-20 2019-04-09 西达-赛奈医疗中心 治疗或预防阿尔茨海默病和相关病况的方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
SG11202103794QA (en) 2018-11-21 2021-05-28 Ionis Pharmaceuticals Inc Compounds and methods for reducing prion expression
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US6794414B1 (en) * 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
DK1294390T3 (da) * 2000-06-07 2006-04-03 Yeda Res & Dev Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
IL148202A0 (en) * 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
MXPA03010327A (es) * 2001-05-17 2004-02-17 Applied Research Systems USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS.
US7718699B1 (en) * 2005-03-04 2010-05-18 Broyles Robert H Abscissic acid and derivatives thereof for the treatment of diseases
IL160105A0 (en) * 2001-12-06 2004-06-20 Yeda Res & Dev Vaccine for treatment of motor neurone diseases
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
US7220729B2 (en) * 2004-05-10 2007-05-22 Academia Sinica Huntington's Disease Treatment

Similar Documents

Publication Publication Date Title
JP2007513079A5 (https=)
BRPI0517227B8 (pt) comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
JP2017164557A (ja) 経鼻配送装置
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
MY169492A (en) Improved protofibril selective antibodies and the use thereof
EP2301569A3 (en) Vaccine and method for treatment of neurodegenerative diseases
JP2008538564A5 (https=)
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
ATE461941T1 (de) Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation
HRP20041108B1 (hr) Peptidi povezani sa tumorom koji se vežu na mhc molekule
EP2679235A3 (en) Peptides and related molecules that modulate nerve growth factor activity
JP2011500851A5 (https=)
HRP20150237T1 (hr) Pegilirani fab protiv amiloida-beta
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
JP2010536714A5 (https=)
JP2006506942A5 (https=)
US20210401751A1 (en) Compositions for treating viral infections and methods for same
WO2006017505A3 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
CN107614512B (zh) 用以治疗和/或预防自体免疫疾病和发炎疾病的短合成肽
JP2019537582A5 (https=)
CN110799522A (zh) 用于治疗、改善或预防脑出血的肽及其用途
JP2015512927A5 (https=)
ATE442158T1 (de) Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form
JP2011500776A5 (https=)